CervoMed Inc.
CRVONASDAQHealthcare● Active
$2.91
$-0.03(-1.02%)
Market Cap$26942872
P/E Ratio—
52W High$13.13
52W Low$2.82
CervoMed Inc. (CRVO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRVO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$0.86
Est. -$0.90 · +4.4%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CRVO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.80 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 18, 2026 | -$0.90 | -$0.86 | +4.4% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 13, 2026 | -$0.79 | -$0.88 | -11.4% | $0.00B | $0.00B | -92.8% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.68 | -$0.84 | -23.5% | $0.00B | $0.00B | -61.7% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -$0.57 | -$0.70 | -22.8% | $0.00B | $0.00B | +22.6% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.60 | -$0.56 | +6.7% | $0.00B | $0.00B | +30.7% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$0.67 | -$0.80 | -19.4% | $0.00B | $0.00B | +40.4% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.41 | -$0.55 | -34.1% | $0.00B | $0.00B | +6.7% |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.80
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Beat
EPS Actual
-$0.86
EPS Est.
-$0.90
EPS Surpr.
+4.4%
Revenue
—
Q1 FY2026
Mar 13, 2026Miss
EPS Actual
-$0.88
EPS Est.
-$0.79
EPS Surpr.
-11.4%
Revenue
$0.00B
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.84
EPS Est.
-$0.68
EPS Surpr.
-23.5%
Revenue
$0.00B
Q3 FY2025
Aug 8, 2025Miss
EPS Actual
-$0.70
EPS Est.
-$0.57
EPS Surpr.
-22.8%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$0.60
EPS Surpr.
+6.7%
Revenue
$0.00B
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$0.80
EPS Est.
-$0.67
EPS Surpr.
-19.4%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.55
EPS Est.
-$0.41
EPS Surpr.
-34.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.10 | $-0.10 | $-0.10 | 3 |
| Q3 FY2028 | $-0.09 | $-0.09 | $-0.09 | 2 |
| Q2 FY2028 | $-0.08 | $-0.08 | $-0.08 | 2 |
| Q1 FY2028 | $-0.09 | $-0.09 | $-0.09 | 3 |
| Q4 FY2027 | $-0.52 | $-0.52 | $-0.52 | 2 |
| Q3 FY2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 18, 2026 | +4.4% | $3.44 | $3.04 | -11.63% |
| ▼ Q1 FY2026 | Mar 13, 2026 | -11.4% | $4.33 | $4.25 | -1.85% |
| ▼ Q4 FY2025 | Nov 7, 2025 | -23.5% | $7.29 | $6.92 | -5.08% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -22.8% | $9.34 | $9.85 | +5.46% |
| ▲ Q2 FY2025 | May 12, 2025 | +6.7% | $8.49 | $9.10 | +7.18% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -19.4% | $6.44 | $9.05 | +40.53% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -34.1% | $12.14 | $11.83 | -2.55% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -12.5% | $11.34 | $11.28 | -0.53% |
Q2 FY2026-11.63%
Report Date
May 18, 2026
EPS Beat/Miss
+4.4%
Price Before
$3.44
Price After
$3.04
Q1 FY2026-1.85%
Report Date
Mar 13, 2026
EPS Beat/Miss
-11.4%
Price Before
$4.33
Price After
$4.25
Q4 FY2025-5.08%
Report Date
Nov 7, 2025
EPS Beat/Miss
-23.5%
Price Before
$7.29
Price After
$6.92
Q3 FY2025+5.46%
Report Date
Aug 8, 2025
EPS Beat/Miss
-22.8%
Price Before
$9.34
Price After
$9.85
Q2 FY2025+7.18%
Report Date
May 12, 2025
EPS Beat/Miss
+6.7%
Price Before
$8.49
Price After
$9.10
Q1 FY2025+40.53%
Report Date
Mar 17, 2025
EPS Beat/Miss
-19.4%
Price Before
$6.44
Price After
$9.05
Q4 FY2024-2.55%
Report Date
Nov 12, 2024
EPS Beat/Miss
-34.1%
Price Before
$12.14
Price After
$11.83
Q3 FY2024-0.53%
Report Date
Aug 9, 2024
EPS Beat/Miss
-12.5%
Price Before
$11.34
Price After
$11.28
Avg Beat Reaction-2.23%
Avg Miss Reaction+6.00%
Beat Rate2 / 8 quarters
Largest Move+40.53% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRVO ends December
CervoMed Inc. (CRVO) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-0.86 — beating the analyst consensus of $-0.90 by +4.4%. The next CRVO earnings date is expected around September 1, 2026.
Each quarter, investors track CRVO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRVO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRVO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRVO earnings · 5 questionsCervoMed Inc.'s next earnings report is expected around September 1, 2026. CRVO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRVO historically reports after market close (AMC).
CRVO earnings datewhen is CRVO earningsCRVO next earnings datewhen does CRVO report earningsCRVO earnings calendar
▸ Source: FMP · CervoMed Inc. SEC filings · US GAAP · CervoMed Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026